IND Enabling

Cabaletta Bio

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Cabaletta Bio Receives FDA Fast Track Designation for DSG3-CAART for the Treatment of Mucosal Pemphigus Vulgaris

Lead Product(s): Desmoglein 3 Chimeric AutoAntibody Receptor T cells

Therapeutic Area: Immunology

Highest Development Status: IND Enabling Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 06, 2020

Details:

U.S. FDA has granted Fast Track Designation for DSG3-CAART, the Cabaletta’s lead product for treatment of mucosal pemphigus vulgaris, for improving healing of mucosal blisters in patients with mPV.

Polyneuron Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Polyneuron Receives Approval to Begin Clinical Study With PN-1007 in Anti-MAG Neuropathy

Lead Product(s): PN-1007

Therapeutic Area: Immunology

Highest Development Status: IND Enabling Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 27, 2020

Details:

Regulatory authorities in France, the Netherlands and the UK have approved the clinical trial application for a phase I/IIa study of PN?1007 for the treatment of anti-MAG neuropathy.

Shenzhen Chipscreen Biosciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Chipscreen Biosciences's Original New Drug CS12192: Investigational New Drug (IND) Application Accepted

Lead Product(s): CS12192

Therapeutic Area: Immunology

Highest Development Status: IND Enabling Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 24, 2020

Details:

CS12192 showed significant efficacy in multiple autoimmune disease models in preclinical studies.

Revive Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Revive Provides Update on its Clinical Development Plan for Cannabidiol in the Treatment of Autoimmune Hepatitis

Lead Product(s): Cannabidiol

Therapeutic Area: Immunology

Highest Development Status: IND Enabling Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 18, 2020

Details:

Revive is currently in the process of preparing its Investigational New Drug (“IND”) application for submission to the U.S. Food and Drug Administration (“FDA”) for CBD in the treatment of AIH.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

Product Type

Companies

Cabaletta Bio

Cabaletta Bio Receives FDA Fast Track Designation for DSG3-CAART for the Treatment of Mucosal Pemphigus Vulgaris

Polyneuron Pharmaceuticals

Polyneuron Receives Approval to Begin Clinical Study With PN-1007 in Anti-MAG Neuropathy

Shenzhen Chipscreen Biosciences

Chipscreen Biosciences's Original New Drug CS12192: Investigational New Drug (IND) Application Accepted

Revive Therapeutics

Revive Provides Update on its Clinical Development Plan for Cannabidiol in the Treatment of Autoimmune Hepatitis